6:48 PM
 | 
Jun 18, 2012
 |  BC Extra  |  Top Story

Reconciled PDUFA bill omits REMS provision

Congress released late Monday a reconciled PDUFA reauthorization bill that excludes a pay-for provision in the Senate version of the bill that would have reduced marketing barriers for generics and biosimilars. The provision, opposed by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Industry Organization (BIO), would have prevented branded manufacturers from...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >